TABLE 1.
The relationships between the clinicopathological features of lung adenocarcinoma patients and PD‐L1 protein expression
| Parameters | PD‐L1 positive (n = 32) | PD‐L1 negative (n = 28) | p‐value | PD‐L1 highly positive (n = 12) | PD‐L1 weakly positive (n = 20) | p‐value |
|---|---|---|---|---|---|---|
| Gender | ||||||
| Male | 22 | 20 | >0.05 | 8 | 14 | >0.05 |
| Female | 10 | 8 | 4 | 6 | ||
| Age | ||||||
| ≥55 | 20 | 17 | >0.05 | 7 | 13 | >0.05 |
| <55 | 12 | 11 | 5 | 7 | ||
| TNM stage | ||||||
| I | 5 | 4 | >0.05 | 2 | 3 | >0.05 |
| II | 12 | 10 | 4 | 8 | ||
| III | 15 | 14 | 6 | 9 | ||
| The location of tumors | ||||||
| Left lung | 15 | 13 | >0.05 | 6 | 9 | >0.05 |
| Right lung | 7 | 5 | 3 | 4 | ||
| Left and right lungs | 10 | 10 | 3 | 7 | ||
| Smoking status | ||||||
| Non‐smoker | 18 | 16 | >0.05 | 7 | 11 | >0.05 |
| Smoker | 14 | 12 | 5 | 9 | ||
Abbreviations: PD‐L1: programmed cell death ligand‐1; TNM: clinical/tumor progression stage.